Why did Morgan Stanley lower Datadog's price target?

Due to concerns over slowing cloud spending.

What is Goldman Sachs' rating on Pfizer?

A 'Buy' rating with a $50 price target.

Did Deutsche Bank change its rating on Gilead?

No, it maintained a 'Hold' rating but lowered the price target to $70.

Top Analyst Calls for Monday: Nvidia, Datadog, Pfizer, Gilead

The article highlights the top Wall Street analyst calls for Monday, July 6, 2026, focusing on Nvidia (NVDA), Datadog (DDOG), Pfizer (PFE), and Gilead (GILD).

July 6, 2026

2 min read

Source: 24/7 Wall St.

The first full week of Q3 trading begins with mixed futures as investors return from the July 4 holiday. Here are Monday's top analyst calls:

Nvidia (NVDA)

Bank of America raised its price target on Nvidia from $150 to $180, maintaining a 'Buy' rating. The move is driven by strong demand for AI chips and revenue growth expectations.

Datadog (DDOG)

Morgan Stanley lowered its price target on Datadog from $140 to $120, with an 'Equal-weight' rating. This follows concerns over slowing cloud spending.

Pfizer (PFE)

Goldman Sachs raised its price target on Pfizer from $45 to $50, with a 'Buy' rating. Positive results for new drugs are cited.

Gilead (GILD)

Deutsche Bank lowered its price target on Gilead from $75 to $70, with a 'Hold' rating. Weak sales of HIV drugs are a concern.

What This Means for Investors

These calls reflect divergent outlooks across sectors. Investors are advised to monitor upcoming quarterly reports for further clarity.

Frequently Asked Questions

Bank of America raised Nvidia's price target from $150 to $180.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.